Author

Yo Han Kim

Institution: Mayo Clinic

Observed institutions: Mayo Clinic, Hanmi Pharmaceutical (South Korea)

ORCID: 0000-0002-2378-0068

Observed ORCID: 0000-0002-2378-0068

OpenAlex ID: A5113784098

Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts

2024 · Faizal Z. Asumda, Nellie A. Campbell, et al. · Cancers · 4

First-in-human study of HM95573, a novel oral RAF inhibitor, in patients with solid tumors.

2016 · Yong Sang Hong, Jeeyun Lee, et al. · Journal of Clinical Oncology · 4

Works count: 2

Citation count: 8

H-index: 2

I10-index: